V. N. Vorobyeva

Toxicity and efficacy of biosimilar bevacizumab in the second-line therapy for metastatic colon cancer in routine clinical practice: results of an independent observational study

F. Moiseenko, O. Gladkov, A. Tryakin, 2021 .